Drug Price Trends for ACUVAIL

Average Pharmacy Cost for ACUVAIL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ACUVAIL 0.45% OPHTH SOLUTION	00023-3507-31	10.73674	EACH	2025-04-23
ACUVAIL 0.45% OPHTH SOLUTION	00023-3507-31	10.73674	EACH	2025-03-19
ACUVAIL 0.45% OPHTH SOLUTION	00023-3507-31	10.73674	EACH	2025-02-19
ACUVAIL 0.45% OPHTH SOLUTION	00023-3507-31	10.71694	EACH	2025-01-22

Market Analysis and Price Projections for Acuvail

Overview of Acuvail

Acuvail, also known as ketorolac tromethamine ophthalmic solution, is a member of the ophthalmic anti-inflammatory agents drug class. It is commonly used to treat postoperative ocular inflammation, particularly after cataract surgery. Here’s a detailed analysis of the market and price projections for Acuvail.

Market Context: Ophthalmic Drugs Market

The global ophthalmic drugs market is projected to grow significantly, driven by increasing prevalence of eye diseases and advancements in treatment options. The market was valued at USD 32.9 billion in 2021 and is expected to reach USD 62.55 billion by 2030, growing at a CAGR of 7.4% during the forecast period (2022-2030)[1].

Segment Analysis

In the ophthalmic drugs market, the anti-VEGF segment is a major contributor, expected to grow at a CAGR of 6.2% during the forecast period. However, Acuvail falls under the anti-inflammatory segment, which, while not as dominant as anti-VEGF, still plays a crucial role in postoperative care[1].

Regional Market Dynamics

The U.S. ophthalmic drugs market, where Acuvail is prominently used, was estimated at USD 15.53 billion in 2023 and is anticipated to grow at a CAGR of 7.4% from 2024 to 2030. This growth is driven by the increasing prevalence of eye-related disorders and the aging population[3].

Pricing and Cost Considerations

As of the latest data, the cost for Acuvail 0.45% ophthalmic solution is around $361 for a supply of 30 solutions, depending on the pharmacy. This price is for cash-paying customers and does not include insurance plans. The use of discount cards, such as the Drugs.com Discount Card, can save up to 80% or more off the cost of prescription medicines[2].

Patient Assistance and Copay Programs

Currently, there are no patient assistance programs or copay cards available specifically for Acuvail. However, patients may benefit from general discount programs or other forms of financial assistance through their healthcare providers[2].

Clinical Efficacy and Market Impact

Acuvail has demonstrated significant efficacy in clinical trials. Studies have shown that patients receiving Acuvail had a higher incidence of clearing anterior chamber inflammation and resolving ocular pain compared to those receiving a vehicle solution. This efficacy supports its market presence and demand, particularly in the postoperative care segment[4].

Competitive Landscape

The ophthalmic drugs market is highly competitive, with major players like Bausch and Lomb, Pfizer Inc., and Alcon. The loss of patent exclusivity for several blockbuster medications is expected to impact the market, but companies are adapting by focusing on new research and development and strategic collaborations. For Acuvail, being a brand-name drug without a generic version yet available, it maintains a strong market position but faces potential competition from future generic alternatives[1].

Price Projections

Given the overall growth of the ophthalmic drugs market and the specific demand for postoperative care solutions, the price of Acuvail is likely to remain stable or see moderate increases. Here are some key points to consider:

• Market Growth: The U.S. ophthalmic drugs market's growth rate of 7.4% CAGR suggests a steady demand for ophthalmic solutions, which could support the pricing of Acuvail.
• Competition: The absence of a generic version currently allows Acuvail to maintain its pricing. However, future generic competition could lead to price reductions.
• Regulatory Environment: New FDA guidelines and regulatory approvals can influence pricing strategies. For instance, the Prescription Drug User Fee Act's guidelines may impact the cost structure of ophthalmic drugs[1][3].

Key Takeaways

• Market Growth: The ophthalmic drugs market, including the segment for anti-inflammatory agents like Acuvail, is expected to grow significantly.
• Pricing: Current prices for Acuvail are around $361 for a 30-solution supply, with potential savings through discount programs.
• Clinical Efficacy: Acuvail has shown strong clinical efficacy, supporting its market demand.
• Competitive Landscape: The market is competitive, with potential impacts from patent expirations and future generic competition.

FAQs

1. What is Acuvail used for? Acuvail is used to treat postoperative ocular inflammation, particularly after cataract surgery.

2. How much does Acuvail cost? The cost for Acuvail 0.45% ophthalmic solution is around $361 for a supply of 30 solutions, depending on the pharmacy.

3. Are there any patient assistance programs for Acuvail? Currently, there are no specific patient assistance programs or copay cards available for Acuvail.

4. How effective is Acuvail in clinical trials? Acuvail has shown significant efficacy in clinical trials, with higher incidence of clearing anterior chamber inflammation and resolving ocular pain compared to vehicle solutions.

5. What are the potential impacts on Acuvail pricing in the future? Future generic competition and changes in the regulatory environment could influence the pricing of Acuvail, potentially leading to price reductions or stability depending on market dynamics.

Sources

1. Straits Research: Ophthalmic Drugs Market Size to Grow at a CAGR of 7.4% by 2030
2. Drugs.com: Acuvail Prices, Coupons, Copay Cards & Patient Assistance
3. Grand View Research: U.S. Ophthalmic Drugs Market Size | Industry Report, 2030
4. DailyMed: Label: ACUVAIL- ketorolac tromethamine solution/ drops - DailyMed